Snowden Capital Advisors’s PAVmed PAVM Stock Holding History

Snowden Capital Advisors’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	-$4K	–	1758
2021 Q4	$4K	Buy	+4	New	+$8.7K	﹤0.01%	1758

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Snowden Capital Advisors's PAVM Position: Q1 2022 in Review

Snowden Capital Advisors sold out of PAVmed (PAVM) in Q1 2022, closing a stake of 4 shares — an estimated $4K sold.

Snowden Capital Advisors first reported a position in PAVM in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 94 funds tracked by Wall St. Rank hold PAVM as of Q1 2022.

Snowden Capital Advisors reported no remaining PAVmed position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 4 PAVmed shares in Q1 2022, an estimated $4K.
Snowden Capital Advisors first reported a position in PAVmed in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's PAVmed position peaked at $4K in Q4 2021.
94 funds tracked by Wall St. Rank held PAVmed as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.